Join the Cherab Foundation's free email support discussion list:

For information about communication impairments, see Cherab's partner informational site, Speechville Express

The Late Talker

Read more about The Late Talker, a new book for families of children who are late to talk.

November 5, 2001
Research on Apraxia/Dyspraxia of Speech at the
Cherab Foundation:
Where Did We Come From, What Did We Find and Where Are We Going?

Location: St. Barnabas Ambulatory Center (Click for directions)
Date: Monday, November 5, 2001
Time: 7:00 PM to 8:30 PM

To cover the travel expenditures of the doctors attending this meeting, we are asking for a suggested five dollar per person donation at the door. Please RSVP to Melanie DePoortere at or Suzanne Smolyar at or or call Suzanne at 212-659-0506

Presenters: Cherab Foundation Scientific Staff
Robert Katz, PhD, President, Omega-3 Research Institute, Inc.,
Bethesda, MD
Marilyn Agin, MD, Medical Director, Early Intervention, New York
City, NY
Lori Roth, MA, CCC-SLP, Speech Pathologist, Cherab Foundation, NJ


"Lisa Geng, President, Cherab Foundation had strong faith in what she called "healing power of essential fatty acids (EFAs) in verbal apraxia". She used the internet effectively to share her belief with other parents with apraxic children. By early this summer it was clear that the anecdotal stories should be urgently placed on a scientific basis. She asked Dr. Marilyn Agin and me to suggest scientific approaches to the entire issue of EFA supplementation in verbal apraxia. We set out, through Cherab, to organize the First Conference for Therapy of Verbal Apraxia/Dyspraxia, July 23-24, Headquarters Plaza Hotel, Morristown, New Jersey, documented the outcomes of EFA supplementation through reports by speech pathologists, analyzed the reports, assembled a venerable group of experts and, following their recommendations, undertook the preparations for a randomized, placebo-controlled double blind clinical trial. This trial is absolutely essential to allow broad professional scrutiny of this potential new therapeutic modality. After presenting our findings at the "Fatty Acids in
Neurodevelopmental Disorders-2001," September 20-21, St. Anne's, College, Oxford University, Oxford, U.K., followed by extensive discussions and planning, we assembled the clinical trial group and designed the clinical protocol. The presentation will lead the
audience through the above process and will solicit reactions to the proposed protocol."

Speaker Biographies:

Marilyn C. Agin, MD, Medical Director, Cherab Foundation, graduated from New Jersey Medical School in 1986, followed by a combined residency in Pediatrics and Physical Medicine and Rehabilitation at New York University Medical Center. She is board certified in both fields. Prior to medical school, Dr. Agin received her master's degree in Communication Disorders and was a practicing speech pathologist. Currently, Dr. Agin is the Medical Director of the New York City Early Intervention Program and does private neurodevelopmental evaluations primarily for children with communication disorders, learning disabilities, and autism. She is a member of the New York City chapter of the Committee on Children with Disabilities of the American Academy of Pediatrics (AAP), and has been appointed to the Executive Council of the New York City chapter of the AAP.
Robert Katz, PhD, Director for EFA Research, Cherab Foundation, received his degree in Organic/Medicinal Chemistry from the Hebrew University, Jerusalem in 1972. During his postdoctoral fellowship (1972-1973) at the National Institutes of Health (NIH), Bethesda, Maryland, he worked in computer-assisted drug design of analgesics and molecular pharmacology of neurotransmitters. From 1978 to 1993, Dr. Katz was Director of Metabolic Diseases Research Program, National Institute of Diabetes, and Digestive and Kidney Diseases, NIH, where he administered and managed nation-wide research programs in membrane structure and function, membrane protein crystallization, structural biology (proteomics), enzyme replacement and gene therapy, etc. He organized workshops and conferences in these areas and identified research directions in need of development. Since leaving the NIH full time position (1993), Dr. Katz has developed DHA- and EPA- derivatized polycationic-lipophilic drug carriers to the CNS. In 1998 he founded the Omega-3 Research Institute, Inc. (O3RI), where he co-organized international workshops on omega-3 fatty acids in brain function, in diabetes and its cardiovascular complications, in molecular and cellular aspects of cancer and recently in verbal apraxia/dyspraxia. During the last year Dr. Katz founded the Consortium for Brain Fatty Acids, O3RI, a "center without walls" that is providing a broad range of expert research support to parties that require such. Dr. Katz is currently a consultant to the National Institutes of Health. In addition, Dr. Katz is co-developing the Cherab Foundation's EFA-based programs.
Lori L. Roth, MA, CCC-SLP, is a Cherab Foundation Speech-Language
Pathologist and Oral Motor Specialist with over 25 years of experience. She received her BA degree in Psychology from G. Washington University in Washington, D.C. in 1972. In 1974 she was awarded her Masters of Speech and Audiology from the Catholic University of America in Washington, DC. Ms. Roth's experience includes home- and hospital-based rehabilitation, private and public school intervention and private practice. Lori Roth was instrumental in establishing an Infant Stimulation Program (called Early Intervention) in Annapolis, Maryland. She has mentored and trained graduate students in Speech and Language Pathology from New York University, Columbia University, Montclair State University and The College of New Jersey as well as practicing therapists in the State of New Jersey. Ms. Roth has presented professional workshops for colleagues and regularly acts as a consultant for private and public schools.

The Cherab Foundation is a world-wide nonprofit organization working to improve the communication skills and education of all children with speech and language delays and disorders. Our area of emphasis is verbal and oral apraxia, severe neurologically-based speech and language disorders that hinder children's ability to speak.

The Foundation is committed to assisting with the development of new therapeutic approaches, preventions and cures to neurologically-based speech disorders. We bring together parents and medical, research, and educational professionals. Please join us and help to give our children a smile and a voice.

Join the Cherab Foundation's free email support discussion list

Cherab Foundation
Communication Help, Education, Research, Apraxia Base
P.O. Box 8524
PSL, Florida 34952-8524
Phone: 772-335-5135

Disclaimer | Privacy Statement | Site Compliance
Last Update: October 12, 2002